Women’s Health Diagnostics Market
Global Women’s Health Diagnostics Market Size, Share & Trends Analysis Report by Diagnostic Devices(Biopsy Devices, and Tests) by Application (Breast Cancer Testing, PAP Smear (PAP) and HPV Test, Infectious Disease Testing, Osteoporosis Testing, Pregnancy, and Fertility Testing, Sexually Transmitted Disease Testing, and Others) and by End-User (Home Care, Hospitals & Clinics, and Diagnostic and Imaging Centers) Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The global women's health diagnostics market is anticipated to grow at a significant CAGR of 7.5% during the forecast period. The increasing prevalence of women’s health diseases such as osteoporosis, menstrual disorders, infertility, PCOD, menopause, brest cancer and othersis attributed to augmenting the market growth. Due to technological improvements in diagnostics devices and high awareness regarding the adoption of preventive care, the women’s heath diagnostics market is projected to grow more.. There is a great prevalence of female cancers such as cervical cancer, it is been treated early and effectively if women are screened effectively. For instance, according to data released by the American cancer society(ACS) in the US, in 2021, there were an estimated 14,480 new cases of cervical cancer diagnosed. Such prevalence of female diseases has led to growth in demand for women's health devices for diagnosis.
Furthermore, the awareness about several women's diseases and related diagnostics imaging procedures is low in under developing countries and this is the factor that may hamper the market growth. . In addition, the high cost of high cost of diagnostics tests and lack of skilled professional to operate diagnostic devices can further limit their adoption on wider level. An increasing number of government initiatives to promote women health awareness and regulatory approvals for immunoassay diagnostic techniques is likely to offer lucrative growth opportunities in the market.
Impact of COVID-19 Pandemic on Global Women's Health Diagnostics Market
The COVID-19 pandemic negatively impacted the market. Restriction on transporation resulted less patient visits in hospitals. Major women diagnostic procedure such as Advanced obstetric ultrasound, Alpha fetoprotein (AFP) blood test., Anorectal manometry, Breast MRI. And others were being postponed and severely restricted at hospitals in order to avoid spreading of virus. According to an online survey that was published by the Journel Breast Cancer Research and Tretament, 44% of the breast cancer survivors experienced delay in care. In addition, so many mamogarms, breast cancer surgeries and other tretaments were delayed, changed and cancelled. This lead to the significant decline in these procedures and impacted the diagnosis market.
Segmental Outlook
The global women’s health diagnostics market is segmented based on diagnostic devices, application, and end-user. On the basis of diagnostic devices, the market is segmented into biopsy devices andtests. Based on the application, the market is sub-classified into cancer testing, pap smear (PAP) and HPV test, infectious disease testing, osteoporosis testing, pregnancy, and fertility testing, sexually transmitted disease testing, and others. Based on the end-user, the market is sub-divided into home care, hospitals & clinics, and diagnostic and imaging centers. Among the end-user segment, the home care segment is expected to be the fastest-growing due to the rising usage of women's health devices in home settings owing to ease and convenience for the patients. Moreover, the growth in home diagnosis devices is anticipated to increase the home care market.
Global Women's Health Diagnostics Market Share by Technique, 2021 (%)
The Breast Cancer Testing Segment is Dominating the Global Women's Health Diagnostics Market
The increasing burden of breast cancer, rising investments in research and development, and advancements in cancer diagnosis are the driving factor for the breast cancer testing segment growth. As per the report by Globocan, in 2020, approximately 2.26 million new breast cancer cases were in womens reported across the globe that was 11.7% of the total cancer cases.. Furthermore, several product launches are another such factor to drive the growth of the segment. For instance, in January 2021, Roche launched, CE-IVD approved automated digital pathology algorithms, uPath HER2 (4B5) image analysis, and uPath HER2 Dual ISH image analysis for breast cancer. These new algorithms will help in determining the best treatment strategy for each patient. Moreover, several government launches are augmenting the market growth. For instance, in October 2021, World Health Organization (WHO), launched a new interactive chatbot on women's health with messaging on breast cancer. This chatbot uses the Viber platform to deliver health information directly to subscribers' mobile phones, that is the latest in a series.
Regional Outlooks
The global women's health diagnostics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East &Africa, and Latin America. North America is expected to dominate due to the increasing incidence of lifestyle-related disorders, high prevalence of cancer among women, significantadoption of advanced technology, product launches, and government initiatives are such factors for the regional dominance.
Global Women's Health Diagnostics Market Growth, by Region 2022-2028
The Asia-Pacific Region is Fastest Growing in the Global Women's Health Diagnostics Market
Improvement in healthcare infrastructure, increasing awareness about women’s health disorders, several government initiatives, are some of the factors that are poised to positively influence the growth of the Asia Pacific region. Moreover, rising awareness about technologically advanced women's health devices is propelling the market to be the fastest growing. For instance, in January 2020, Sysmex has received regulatory approval from China's National Medical Products Administration (NMPA) for LYNOAMP™ BC Vitro diagnostic reagent. It is to test for breast cancer lymph node metastasis using the OSNA™ method which has been received Class III1 regulatory approval as the first product for lymph node metastasis testing using a molecular biological technique first as ever. This type of prominent product is approved in the region and such mentioned factors are increasing the demand for women's diagnostic and propelling the women's health diagnostic market to grow.
Market Players Outlook
The major companies serving the global women's health diagnostics market include F. Hoffmann-La Roche Ltd, General Electric Co., Hologic, Inc., Myriad Genetics, Inc., MedGyn Products, Inc., and PerkinElmer Inc., Siemens Medical Solutions USA, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2021, Carestream Health and Ziehm Imaging Americas partnered, to distribute the Ziehm Vision RFD in Carestream Health surgical imaging system that will further enhance Carestream's mobile and fluoroscopic product offerings. This system will benefit even more healthcare providers will be available in the U.S. and Canada in 2021. It offers a 25kw generator, in either a 20.5 x 20.5 cm or 31 x 31 cm field of view flat-panel CMOS digital detector, and allows for broad procedural work that includes vascular, cardiac, spine ortho-trauma, and pain management.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global women's health diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Women’s Health Diagnostics Market
• Recovery Scenario of Global Women’s Health Diagnostics Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. F. Hoffmann-La Roche Ltd
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. General Electric Co.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Hologic, Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. PerkinElmer Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Siemens Medical Solutions USA, Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Women’s Health Diagnostics Market by Type
4.1.1. Diagnostic Devices
4.1.2. Diagnostic Tests
4.2. Global Women’s Health Diagnostics Market by Application
4.2.1. Breast Cancer Testing
4.2.2. PAP Smear (PAP) and HPV Test
4.2.3. Infectious Disease Testing
4.2.4. Osteoporosis Testing
4.2.5. Pregnancy and Fertility Testing
4.2.6. Sexually Transmitted Disease Testing
4.2.7. Other
4.3. Global Women’s Health Diagnostics Market by End-User
4.3.1. Home Care
4.3.2. Hospitals & Clinics
4.3.3. Diagnostic and Imaging Centers
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Becton, Dickinson and Co
6.3. BIOMÉRIEUX, INC.
6.4. Bio-Rad Laboratories, Inc.
6.5. BOSTON IMAGING
6.6. Canon Medical Systems Corp.
6.7. Carestream Health, Inc.
6.8. Cook Group Inc
6.9. DiaSorin S.p.A
6.10. Grifols, S.A.
6.11. Konica Minolta Healthcare Americas, Inc.
6.12. Laboratory Corp.
6.13. Myriad Genetics, Inc.
6.14. MedGyn Products, Inc.
6.15. Ortho Clinical Diagnostics
6.16. Philips International B.V.,
6.17. Quest Diagnostics
6.18. Thermo Fisher Scientific Inc.
6.19. Ziehm Imaging GmbH
1. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL WOMEN’S HEALTH DIAGNOSTICS DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL WOMEN’S HEALTH DIAGNOSTICS TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($MILLION)
4. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
5. GLOBAL BREAST CANCER TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL PAP SMEAR (PAP) AND HPV TEST IN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($MILLION)
7. GLOBAL PREGNANCY AND FERTILITY TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($MILLION)
8. GLOBAL SEXUALLY TRANSMITTED DISEASE TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($MILLION)
9. GLOBAL INFECTIOUS DISEASE TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL OSTEOPOROSIS TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL OTHERS WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
13. GLOBAL WOMEN’S HEALTH DIAGNOSTICS IN HOME CARE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL WOMEN’S HEALTH DIAGNOSTICS IN HOSPITALS & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL WOMEN’S HEALTH DIAGNOSTICS IN DIAGNOSTIC AND IMAGING CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. NORTH AMERICAN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. NORTH AMERICAN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY Dignostic device, 2021-2028 ($ MILLION)
18. NORTH AMERICAN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
19. NORTH AMERICAN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
20. EUROPEAN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. EUROPEAN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY DIGNOSTIC DEVICE, 2021-2028 ($ MILLION)
22. EUROPEAN WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
23. EUROPEAN WOMEN’S HEALTH DIAGNOSTICSMARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
24. ASIA-PACIFIC WOMEN’S HEALTH DIAGNOSTICSMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY DIGNOSTIC DEVICE, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC WOMEN’S HEALTH DIAGNOSTICSMARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
28. REST OF THE WORLD WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
29. REST OF THE WORLD WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY DIGNOSTIC DEVICE, 2021-2028 ($ MILLION)
30. REST OF THE WORLD WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST,2021-2028 ($ MILLION)
31. REST OF THE WORLD WOMEN’S HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER,2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET, 2021-2028 (%)
4. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL WOMEN’S HEALTH DIAGNOSTICS DEVICES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL WOMEN’S HEALTH DIAGNOSTICS TESTSMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
8. GLOBAL BREAST CANCER TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL PAP SMEAR (PAP) AND HPV TEST IN WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY, 2021 VS 2028 (%)
10. GLOBAL PREGNANCY AND FERTILITY TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL INFECTIOUS DISEASE TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL OSTEOPOROSIS TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL SEXUALLY TRANSMITTED DISEASE TESTING IN WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL WOMEN’S OTHER HEALTH DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY END-USER, 2021 VS 2028 (%)
16. GLOBAL WOMEN’S HEALTH DIAGNOSTICS IN HOME CARE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL WOMEN’S HEALTH DIAGNOSTICS IN HOSPITALS & CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL WOMEN’S HEALTH DIAGNOSTICS IN DIAGNOSTIC AND IMAGING CENTERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. GLOBAL WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
20. US WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
21. CANADA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
22. UK WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
23. FRANCE WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
24. GERMANY WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
25. ITALY WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
26. SPAIN WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF EUROPE WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
28. INDIA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
29. CHINA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
30. JAPAN WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
31. SOUTH KOREA WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
32. REST OF ASIA-PACIFIC WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
33. REST OF THE WORLD WOMEN’S HEALTH DIAGNOSTICS MARKET SIZE, 2021-2028 ($ MILLION)
